Publications 2009 - 2012

2009

  1. Tanteles, G., Whitworth, J., Mills, J., Peat, I., Osman, A., McCann, G. P., . . . Symonds, R. P. (2009, August 8). Can cutaneous telangiectasiae, as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer.. British Journal of Cancer, 101(3), 403-409. doi:10.1038/sj.bjc.6605182 

2010

  1. Cox, D. G., Barjhoux, L., Verny-Pierre, C., Mazoyer, S., Sinilnikova, O. M., Cox, D. G., Vénat-Bouvet, L. (2011, December). Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 20(23), 4732-4747. doi:10.1093/hmg/ddr388 
  2. Bancroft, E. K., Ardern Jones, A., Shanley, S., D'Mello, L., McReynolds, K., A'Hern, R., Eeles, R. A. (2010, July 7). Clinical Events and Decision-Making in BRCA1/2 carriers post-genetic testing: Rationale for a Carrier Clinic Model.. Unknown Journal, 47(7), 486-491. 
  3. Bancroft, E. K., Locke, I., Ardern-Jones, A., D'Mello, L., McReynolds, K., Lennard, F., Eeles, R. A. (2010, July). The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.. J Med Genet, 47(7), 486-491. doi:10.1136/jmg.2009.072728

2011

  1. Mulligan, A. M., Couch, F. J., Barrowdale, D., Domchek, S. M., Eccles, D., Nevanlinna, H., CIMBA. (2011). Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.. Breast Cancer Res, 13(6), R110. doi:10.1186/bcr3052
  2. Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Rahman, N. (2011, September). Germline mutations in RAD51D confer susceptibility to ovarian cancer.. Nat Genet, 43(9), 879-882. doi:10.1038/ng.893
  3. Murray, R. J., Tanteles, G. A., Mills, J., Perry, A., Peat, I., Osman, A., Talbot, C. J. (2011, May). Association between single nucleotide polymorphisms in the DNA repair gene LIG3 and acute adverse skin reactions following radiotherapy.. Radiother Oncol, 99(2), 231-234. doi:10.1016/j.radonc.2011.05.007
  4. Antoniou, A. C., Kartsonaki, C., McGuffog, L., Lee, A., Peock, S., Cook, M., Smalley, S. (2011, August). Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 20(16), 3304-3321. doi:10.1093/hmg/ddr226

2012

  1. Tanteles, G. A., Murray, R. J., Mills, J., Barwell, J., Chakraborti, P., Chan, S., Symonds, R. P. (2012, November 15). Variation in telangiectasia predisposing genes is associated with overall radiation toxicity.. Int J Radiat Oncol Biol Phys, 84(4), 1031-1036. doi:10.1016/j.ijrobp.2012.02.018
  2. Turnbull, C., Seal, S., Renwick, A., Warren-Perry, M., Hughes, D., Elliott, A., . . . Barwell, J. (2012, February 15). Gene-gene interactions in breast cancer susceptibility.. Hum Mol Genet, 21(4), 958-962. doi:10.1093/hmg/ddr525
  3. Pal, R. P., Hollox, E. J., Cresswell, L., Pringle, J. H., Veal, C. D., Hew, R., . . . Barwell, J. G. (2012, February). ERG immunocytochemistry can identify prostate cancer patients prior to prostate biopsy. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E424-U930.
  4. Evans, D. G., Raymond, F. L., Barwell, J. G., & Halliday, D. (2012, November). Genetic testing and screening of individuals at risk of NF2.. Clin Genet, 82(5), 416-424. doi:10.1111/j.1399-0004.2011.01816.x

 

Share this page:

NEWS

Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform

---------------------------------

SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper

---------------------------------

Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair jm65@le.ac.uk

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170
E: cancerstudies@le.ac.uk

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 
LE1 5WW

Accessibility

AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.

Seminars

.